 | |
| Clinical data | |
|---|---|
| Other names | LY-293,558; LY-293558; LY293558; LY-326,325; LY-326325; LY326325; NGX-424; NGX424 |
| Routes of administration | IV |
| ATC code |
|
| Legal status | |
| Legal status |
|
| Identifiers | |
| |
| CAS Number | |
| PubChemCID | |
| IUPHAR/BPS | |
| ChemSpider |
|
| UNII | |
| KEGG |
|
| ChEMBL | |
| Chemical and physical data | |
| Formula | C13H21N5O2 |
| Molar mass | 279.344 g·mol−1 |
| 3D model (JSmol) | |
| |
| |
 N Y (what is this?) (verify) | |
Tezampanel (INNTooltip International Nonproprietary Name,USANTooltip United States Adopted Name) (developmental code namesLY-293,558,LY-326,325,NGX-424) is adrug originally developed byEli Lilly[1] which acts as acompetitive antagonist of theAMPA andkainate subtypes of theionotropic glutamate receptor family,[2][3] with selectivity for theGluR5 subtype of the kainate receptor.[4][5] It hasneuroprotective[6] andanticonvulsant properties,[7] the former of which may, at least in part, occur via blockade ofcalciumuptake intoneurons.[8]
Tezampanel has a range of effects which may be useful formedicinal purposes, as well as its applications inscientific research. It suppresses both thewithdrawalsymptoms frommorphine and otheropioids,[9][10][11] and the development oftolerance,[12] as well as havingantihyperalgesic[13] andanalgesic effects in its own right.[14][15][16][17][18] It also hasanxiolytic effects inanimal studies and has been suggested as a candidate for the treatment ofanxiety in humans.[19]
Whereas tezampanelfree base is known asLY-293558, tezampanelhydrochloride is said to be known asLY-326325.[20][21]